Over the past eighteen months, there has been a growing appreciation among our partners and peers of our unique expertise in functions essential to the development and advancement of antibody-based anticancer compounds. To provide the support our partners need and are willing to fund, and to provide internal support for our own compounds, we have expanded our human and physical resources in selected areas.

We have established an internal clinical department to lead the clinical development of huN901-DM1 and cantuzumab mertansine and to provide input on other compounds in development. It is headed by a well respected oncologist with extensive experience both in cancer drug development and in the practice of clinical oncology.

We have bolstered our regulatory department, both to support our own clinical-stage compounds and to assist partners with those aspects of regulatory submissions unique to TAP compounds.

We have expanded our manufacturing capacity and are adding more production personnel. We also have increased our headcount in manufacturing-related areas such as process development, analytical assay development, and quality systems.

We believe we are well positioned – in our human resources, our physical resources, and our financial resources – to advance our own compounds and to support our partners in the advancement of theirs. We are committed to the development of high-value anticancer products that can make a real difference to patients.